<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125302</url>
  </required_header>
  <id_info>
    <org_study_id>3110-305-002</org_study_id>
    <nct_id>NCT05125302</nct_id>
  </id_info>
  <brief_title>Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is a common neurological disorder typically characterized by attacks of throbbing,&#xD;
      moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light&#xD;
      and sound. Migraine is extremely common and disabling in children. The purpose of this study&#xD;
      is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in&#xD;
      children and adolescents.&#xD;
&#xD;
      Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and&#xD;
      adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will&#xD;
      include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants&#xD;
      aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis&#xD;
      to determine dose selection for the main study. In the main study, after dose selection,&#xD;
      children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant&#xD;
      or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo.&#xD;
      Adolescents aged 12-17 years will be randomized to receive either low or high dose of&#xD;
      Ubrogepant or placebo with a 1 in 3 chance of placebo assignment.&#xD;
&#xD;
      For qualifying migraine attacks, participants will receive oral tablets of the double-blind&#xD;
      study intervention. There will be an option to take a second dose of double-blind study&#xD;
      intervention (identical to initial dose), or rescue medication, 2 to 24 hours after the&#xD;
      initial dose, for headache of moderate/severe intensity. Around 1059 participants will be&#xD;
      enrolled in the study in approximately 120 sites in the United States. The study duration&#xD;
      will be up to 6 months.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 9, 2021</start_date>
  <completion_date type="Anticipated">May 13, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 12 to 17 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Pain Relief at 2 Hours After the Initial Dose in pediatric participants aged 12 to 17 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Pain Relief is defined as a reduction in headache severity from moderate/severe at baseline to mild or no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>2 to 24 hours after initial dose</time_frame>
    <description>Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants that used rescue medication (including a second dose of study intervention) within 24 hours after the initial dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>24 hours after initial dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>Baseline (Predose) to 2 hours after initial dose</time_frame>
    <description>The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose in pediatric participants aged 12 to 17 years</measure>
    <time_frame>Baseline (Predose) to 2 hours after initial dose</time_frame>
    <description>The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 11 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Photophobia was defined as sensitivity to light, a migraine-associated symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Phonophobia was defined as sensitivity to sound, a migraine-associated symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Absence of Nausea at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years</measure>
    <time_frame>2 hours after initial dose</time_frame>
    <description>Nausea was a migraine-associated symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AE)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed in pediatric participants aged 6 to 17 years</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Percentage of participants with abnormal change in clinical laboratory test results like hematology will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiograms (ECGs) in pediatric participants aged 6 to 17 years</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements in pediatric participants aged 6 to 17 years</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Percentage of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with suicidal ideation or suicidal behavior</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">1059</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>PK Cohort: Ubrogepant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PK Cohort: Ubrogepant Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Children Ubrogepant Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to 11 (after dose selection) will receive oral tablets of low dose ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Children Ubrogepant High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to 11 (after dose selection) will receive oral tablets of high dose ubrogepant Dose B for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Children Ubrogepant Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 6 to 11 (after dose selection) will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Adolescents Ubrogepant Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 17 will receive oral tablets of ubrogepant low dose for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Adolescents Ubrogepant High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 17 will receive oral tablets of ubrogepant high dose or qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Adolescents Ubrogepant Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 12 to 17 will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of moderate/severe intensity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ubrogepant</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Main Study: Adolescents Ubrogepant High Dose</arm_group_label>
    <arm_group_label>Main Study: Adolescents Ubrogepant Low Dose</arm_group_label>
    <arm_group_label>Main Study: Children Ubrogepant High Dose</arm_group_label>
    <arm_group_label>Main Study: Children Ubrogepant Low Dose</arm_group_label>
    <arm_group_label>PK Cohort: Ubrogepant Dose A</arm_group_label>
    <arm_group_label>PK Cohort: Ubrogepant Dose B</arm_group_label>
    <other_name>Ubrelvy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Matching Ubrogepant</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Main Study: Adolescents Ubrogepant Placebo</arm_group_label>
    <arm_group_label>Main Study: Children Ubrogepant Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A history of migraine with or without aura consistent with a diagnosis according to&#xD;
             the International Classification of Headache Disorders (ICHD-3) for at least 6 months.&#xD;
&#xD;
          -  By history, the participant's migraines typically last between 3 and 72 hours if&#xD;
             untreated or treated unsuccessfully and migraine episodes are separated by at least 48&#xD;
             hours of headache pain freedom.&#xD;
&#xD;
          -  History of 1 to 14 migraine attacks per month with moderate to severe headache in each&#xD;
             of the 2 months prior to screening (Visit 1).&#xD;
&#xD;
          -  Current or past use of at least 1 oral medication (over-the-counter medication or&#xD;
             prescription medication) for the acute treatment of migraine.&#xD;
&#xD;
          -  For main study participants, treatment of a qualifying migraine with single-blind&#xD;
             placebo during the screening period and completion of 2-hour headache pain assessment.&#xD;
&#xD;
          -  Weight is ≥ 20 kg (44 pounds) and &lt; 135 kg (298 pounds)&#xD;
&#xD;
          -  Per investigator judgment, participant is able to swallow or can learn to swallow&#xD;
             study intervention.&#xD;
&#xD;
          -  The participant is able to understand and complete the study questionnaires and&#xD;
             eDiary. Participants who need assistance with reading the assessments may be assisted&#xD;
             by a parent or guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, cardiovascular or neurologic disease.&#xD;
&#xD;
          -  In the opinion of the investigator, other confounding pain syndromes, confounding&#xD;
             psychiatric conditions, or other significant neurological disorders other than&#xD;
             migraine.&#xD;
&#xD;
          -  History of malignancy in the 5 years prior to Visit 1.&#xD;
&#xD;
          -  History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory&#xD;
             bowel disease) that may affect the absorption or metabolism of the study intervention.&#xD;
&#xD;
          -  Significant risk of self-harm, based on clinical interview and responses on the&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others; participants&#xD;
             must be excluded if they report suicidal ideation with intent, with or without a plan,&#xD;
             (ie, Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in&#xD;
             the last 6 months prior to Visit 1 or Visit 2 assessments.&#xD;
&#xD;
          -  At Visit 1, current alcohol or drug abuse or dependence per investigator's judgment.&#xD;
&#xD;
          -  For main study participants, no headache at the 2-hour post dose assessment after&#xD;
             taking single-blind placebo for a qualifying migraine during screening period (ie,&#xD;
             placebo responder).&#xD;
&#xD;
          -  A current diagnosis of chronic migraine as defined by ICHD-3&#xD;
&#xD;
          -  Participants who overuse medication for migraine defined as use of opioids or&#xD;
             barbiturates &gt; 2 days/month, triptans or ergots ≥ 10 days/month, simple analgesics&#xD;
             (eg, aspirin, NSAIDs, acetaminophen) ≥ 15 days/month or any combination of triptans,&#xD;
             ergots, or simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 10 days/month in&#xD;
             the 3 months prior to Visit 1 per investigator's judgment.&#xD;
&#xD;
          -  Difficulty distinguishing migraine headache from tension-type or other headaches.&#xD;
&#xD;
          -  Has a history of migraine aura with diplopia or impairment of level of consciousness,&#xD;
             hemiplegic migraine, or retinal migraine as defined by ICHD-3.&#xD;
&#xD;
          -  Has a current diagnosis of new persistent daily headache, trigeminal autonomic&#xD;
             cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3&#xD;
&#xD;
          -  Required in-hospital (excluding emergency department visits) treatment for migraines 3&#xD;
             or more times in the 6 months prior to Visit 1.&#xD;
&#xD;
          -  Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice) that&#xD;
             is on the list of prohibited concomitant medications that cannot be discontinued or&#xD;
             switched to an allowable, alternative medication at Visit 1.&#xD;
&#xD;
          -  Previous exposure, within the last 6 months, to injectable monoclonal antibodies&#xD;
             blocking the calcitonin gene-related peptide (CGRP) pathway&#xD;
&#xD;
          -  History of hypersensitivity or clinically significant adverse reaction to a CGRP&#xD;
             receptor antagonist or hypersensitivity to any component of the study interventions,&#xD;
             ubrogepant or placebo.&#xD;
&#xD;
          -  Currently participating or has participated in a study with an investigational&#xD;
             compound or device within 30 days prior to Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rehabilitation &amp; Neurological Services /ID# 229969</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805-4046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Trials - Saraland /ID# 231546</name>
      <address>
        <city>Saraland</city>
        <state>Alabama</state>
        <zip>36571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Research Partners /ID# 230725</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group /ID# 230873</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center /ID# 227962</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center /ID# 227966</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunwise Clinical Research /ID# 230971</name>
      <address>
        <city>Lafayette</city>
        <state>California</state>
        <zip>94549-4579</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research /ID# 230546</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles /ID# 230596</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc /ID# 230899</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumos Clinical Research Center /ID# 231267</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124-4108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research Management Group /ID# 231636</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786-3676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado /ID# 231879</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe Research Centers /ID# 230879</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers /ID# 231625</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Denver /ID# 232035</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209-3804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research /ID# 230635</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905-1224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Inst /ID# 231693</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Clinical Research Center /ID# 230020</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials /ID# 227956</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.G.A Clinical Trials /ID# 230554</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute of Miami /ID# 230292</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030-4613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multi-Speciality Research Associates /ID# 229595</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055-8835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auzmer Research /ID# 239251</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33813-2768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Services, Llc /Id# 230880</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125-5114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biotech Pharmaceutical Group /ID# 227886</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Research Group /ID# 231160</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology &amp; Pain Medicine /ID# 240168</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186-7661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida /ID# 231632</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research - Palm Harbor /ID# 229337</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioresearch Institute LLC /ID# 230909</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026-4383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Urgent Care - Pembroke Pines /ID# 239977</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029-2818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asclepes Research Centers - Spring Hill /ID# 229815</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609-5692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Trials - West Broward Outpatient Research Site /ID# 231930</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33319-4985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida /ID# 229324</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research /ID# 227992</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology PA /ID# 229967</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789-7111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC /ID# 231046</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318-2512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 231134</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328-5574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Georgia Child Neurology /ID# 231409</name>
      <address>
        <city>Brunswick</city>
        <state>Georgia</state>
        <zip>31520-1601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC /ID# 227903</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research LLC /ID# 228992</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 231738</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Boise /ID# 231871</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of McFarland /ID# 229789</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010-5733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College Park Family Care Center Overland Park /ID# 231456</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210-2761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates /ID# 230872</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research (AMR) - Wichita West /ID# 234126</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205-1138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center /ID# 230827</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research, Inc. /ID# 227908</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Headache &amp; Neurological Institute (MHNI) /ID# 229150</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104-5131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroBehavioral Medicine Group /ID# 231149</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology - Burnsville /ID# 232551</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337-6732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc /ID# 227872</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402-2606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSync Clinical Research Hattiesburg Clinic /ID# 233326</name>
      <address>
        <city>Petal</city>
        <state>Mississippi</state>
        <zip>39465-2932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Neurology Research Institute /ID# 239513</name>
      <address>
        <city>Ridgeland</city>
        <state>Mississippi</state>
        <zip>39157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharlin Health Neuroscience Research Center /ID# 229523</name>
      <address>
        <city>Ozark</city>
        <state>Missouri</state>
        <zip>65721-5315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials (CCT) - Papillion /ID# 232552</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046-4131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthy Perspectives - Innovative Mental Health Services, PLLC /ID# 230312</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060-3483</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goryeb Children's Hospital /ID# 229507</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CVS HealthHUB - Runnemede /ID# 234233</name>
      <address>
        <city>Runnemede</city>
        <state>New Jersey</state>
        <zip>08078-1034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center, Inc. /ID# 231182</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioscience Research /ID# 232159</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549-3028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suffolk Neurology /ID# 230956</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776-3387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University /ID# 239898</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CVS HealthHUB - Charlotte /ID# 239530</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions, LLC - Charlotte /ID# 227994</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites, LLC /ID# 238485</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215-2123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 231199</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Columbus /ID# 231181</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CincyScience /ID# 230046</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company /ID# 227961</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute (LHSI) /ID# 239134</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sooner Clinical Research /ID# 227960</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute /ID# 231607</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225-6625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - Main /ID# 232487</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC - Scottdale /ID# 231913</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <zip>15683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research /ID# 231912</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research - West Ashley A /ID# 238616</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414-5834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research LLC /ID# 230422</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607-4021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Neurology, P.C. /ID# 227999</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Access Clinical Trials, Inc. /ID# 228002</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin /ID# 230529</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759-5290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research - Beaumont /ID# 231207</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77706-3067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Austin /ID# 230557</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613-3513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Relaro Medical Trials /ID# 239642</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Health Research /ID# 228003</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251-2202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3A Research - East El Paso /ID# 239193</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925-7945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Earle Research /ID# 231548</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058-2746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research /ID# 229826</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Trials Worldwide /ID# 230896</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338-3501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMC Science /ID# 231915</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIM Trials /ID# 230142</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practical Approach Pediatrics /ID# 238869</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research /ID# 230527</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249-3538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of The Woodlands /ID# 230163</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPoint Trials /ID# 230295</name>
      <address>
        <city>Waxahachie</city>
        <state>Texas</state>
        <zip>75165-1430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research /ID# 239362</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine /ID# 230908</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates LLC/DBA Woodstock Research Center /ID# 238976</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Maria Ona /ID# 234232</name>
      <address>
        <city>Franklin</city>
        <state>Virginia</state>
        <zip>23851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters - Children's Medical Tower /ID# 230581</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507-1901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research /ID# 231320</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Core Clinical Research /ID# 227904</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research - Kingwood /ID# 231914</name>
      <address>
        <city>Kingwood</city>
        <state>West Virginia</state>
        <zip>26537-9797</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Ubrogepant</keyword>
  <keyword>Ubrelvy</keyword>
  <keyword>PERISCOPE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

